Jonathan Rothbard
Founder bei 180 LIFE SCIENCES CORP.
Vermögen: 3 437 $ am 31.03.2024
Profil
Dr. Jonathan B.
Rothbard is a Chief Executive Officer, Director & CSO at Katexco Pharmaceuticals Corp., a Chief Scientific Officer at 180 Life Sciences Corp.
and a Director, Chief Executive & Scientific Officer at CannBioRex Pharmaceuticals Corp.
He is on the Board of Directors at Katexco Pharmaceuticals Corp.
and CannBioRex Pharmaceuticals Corp.
Dr. Rothbard was previously employed as a Chief Scientific Officer by KBL Merger Corp.
IV, a Chief Scientific Officer by Cellgate, Inc., a Founder by Amylin Pharmaceuticals, Inc., a Chief Scientific Officer-Palo Alto by ImmuLogic Pharmaceutical Corp., and a Head-Molecular Immunology Laboratory by Imperial Cancer Research Fund Trading Ltd.
He received his undergraduate degree from Hamilton College (New York) and a doctorate degree from The Trustees of Columbia University in The City of New York.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
180 LIFE SCIENCES CORP.
0,17% | 18.12.2023 | 1 475 ( 0,17% ) | 3 437 $ | 31.03.2024 |
Aktive Positionen von Jonathan Rothbard
| Unternehmen | Position | Beginn |
|---|---|---|
| 180 LIFE SCIENCES CORP. | Founder | - |
Katexco Pharmaceuticals Corp.
 Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada. | Chief Executive Officer | 01.11.2018 |
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Jonathan Rothbard
| Unternehmen | Position | Ende |
|---|---|---|
Cellgate, Inc.
 Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Founder | 01.01.2004 |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Founder | 01.01.1995 |
| Imperial Cancer Research Fund Trading Ltd. | Corporate Officer/Principal | - |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Founder | - |
| 180 LIFE SCIENCES CORP. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Jonathan Rothbard
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| Hamilton College (New York) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| 180 LIFE SCIENCES CORP. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Health Technology |
Cellgate, Inc.
Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Health Technology |
KBL Merger Corp. IV
 KBL Merger Corp. IV Financial ConglomeratesFinance KBL Merger Corp. IV is a blank check company, which focuses on acquiring an operating company in the healthcare and related wellness industry. The company was founded on September 7, 2016 and is headquartered in New York, NY. | Finance |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Health Technology |
Katexco Pharmaceuticals Corp.
Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada. | Health Technology |
